The Effects of Using Yupingfeng Powder With Variation for the Treatment of Allergic Rhinitis

Sponsor
Prof. Lin Zhixiu (Other)
Overall Status
Recruiting
CT.gov ID
NCT04976023
Collaborator
(none)
58
1
2
20.6
2.8

Study Details

Study Description

Brief Summary

Allergic rhinitis (AR) is an IgE mediated chronic inflammatory disease of the upper airways characterized by symptoms of sneezing, rhinorrhea, nasal itching, and nasal obstruction . However, not only this disease is difficult to cure, but also its relapse rate is high, therefore exerting a certain impact on their daily life, work and study. Nowadays, the main treatment for allergic rhinitis is the use of western medicine, such as steroids and antihistamines. However, many clinical studies have found that the curative effect of western medicine is often not ideal.

Allergic rhinitis belongs to the category of "Rhinitis" in Chinese medicine. From the perspective of Chinese medicine, this disease is resulted from the deficiency of Qi and Yang Qi in the lungs, spleen and kidneys. Therefore, according to Chinese medicine theory, tonifying lung and spleen qi is the treatment principle for AR patients. Among different Chinese herbal formulae for AR, Yupingfeng san is commonly used for allergic diseases and in AR patients, due to its warm nature and able to improve the functions of the lungs and spleen. Yupingfeng san can improve symptoms and quality of life, as well as decrease the levels of interleukin and IgE in AR patients. This study will use Yupingfeng Powder with variation to evaluate its effectiveness and safety in treating AR. Hence, this study would be able to provide evidence on the efficacy and safety of Yupingfeng Powder with variation for AR.

Condition or Disease Intervention/Treatment Phase
  • Drug: Yupingfeng Powder granules
  • Other: Placebo
Phase 2/Phase 3

Detailed Description

Rhinitis is broadly defined as inflammation of the nasal mucosa. It is a common disorder that affects up to 40% of the population. Allergic rhinitis (AR) is the most common type of chronic rhinitis, affecting 10-20% of the population, and evidence suggests that the prevalence of the disorder is increasing. AR is a very common clinical disease that can occur at any age. Severe allergic rhinitis has been associated with significant impairments in quality of life, sleep and work performance.

Allergic rhinitis is a complex immune and inflammatory disease. Its pathogenesis has not yet been fully known, and there is no clear way to cure. It is an IgE-mediated chronic inflammatory disease of the upper airways characterized by symptoms of sneezing, rhinorrhea, nasal itching, and nasal obstruction, and cytokines such as IL-17 and IL-10 play an essential role in mediating allergic inflammation. Nowadays, the main treatment for allergic rhinitis is the use of western medicine, such as steroids and antihistamines. However, many clinical studies have found that the curative effect of western medicine is often not ideal.

Chinese herbal medicine (CHM) is a well tolerated choice for AR patients seeking complementary and alternative therapies to reduce AR symptoms. In recent years, studies have found that Yupingfeng Powder not only has few side effects (feeling of abdominal distension or increased in acne are reported), it can al so increase anti allergic ability and improve body's resistance, thus showing the advantages of oral Chinese medicine in the treatment of AR. Accordingly, CHM may influence the gastrointestinal system, including the intestinal mucosa and gut microbiota, the latter of which is essential for health and closely linked to diseases. A few systematic reviews and studies indicate that certain probiotics are beneficial for patients with AR.

In this study, fifty-eight eligible subjects will be recruited from Paediatric out-patient clinic and community, and randomly assigned to receive orally Yupingfeng Powder with variation or placebo twice a day for 8 weeks, with follow-up for another 8 weeks after stopping the treatment to observe the duration of efficacy and to explore the mechanism of Yupingfeng Powder in treating AR with respect to the immune response and gut microbiota.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
58 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effects of Using Yupingfeng Powder With Variation for the Treatment of Allergic Rhinitis(AR):a Randomized Controlled Trial
Actual Study Start Date :
Apr 12, 2022
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active Arm

14.55g of Yupingfeng Powder granules twice daily for 8 weeks

Drug: Yupingfeng Powder granules
14.5 5 g twice daily for 8 weeks
Other Names:
  • Yupingfeng Powder with variation
  • Placebo Comparator: Placebo Arm

    14.55g of placebo granules twice daily for 8 weeks

    Other: Placebo
    14.5 5 g twice daily for 8 weeks
    Other Names:
  • Placebo granules
  • Outcome Measures

    Primary Outcome Measures

    1. The change in the Total Nasal Symptom Score (TNSS) [Week 8]

      The TNSS evaluates 4 nasal symptoms ( rhinorrhea, sneezing, nasal obstruction and nasal itching) which will be self assessed by subjects using a four point scale, with low scores indicating less severe nasal symptoms

    Secondary Outcome Measures

    1. The change in the Total Nasal Symptom Score (TNSS) [week 4, week 12 and week 16]

      The TNSS evaluates 4 nasal symptoms ( rhinorrhea, sneezing, nasal obstruction and nasal itching) which will be self assessed by subjects using a four point scale, with low scores indicating less severe nasal symptoms

    2. The changes in frequency of AR episodes and their severity on visual analog scale (VAS) [week 4, week 8, week 12 and week 16]

      The VAS ranges from 0 (nasal symptom free) to 10 (nasal symptom extremely bothersome) to assess the severity of nasal symptom disturbance

    3. The changes in quality of life by using The changes in the Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) [week 4, week 8, week 12 and week 16]

      The lower the score the higher the quality of life

    4. The changes in quality of life by using The changes in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) [week 4, week 8, week 12 and week 16]

      The lower the score the higher the quality of life

    5. The changes in the serum levels of specific IgE [week 8 and week 12]

      The serum levels of cytokines and IgE will be tested. The higher the value, the more severity of the symptoms.

    6. The changes in the serum levels of cytokines (IL-10 and IL-17) [week 8 and week 12]

      Serum responses will correlate with the nasal symptoms scores.

    7. The changes in the gut microbiota composition in stools [week 8]

      The composition of gut microbiota will be tested to observe the influence of Chinese. Gut microbiome compositions will be characterised by shotgun sequencing total DNA extracted from stools.

    8. Adverse events related to study treatment [During study for 16 weeks]

      All adverse events that are related to the study treatment will be captured for analysis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    5 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age d above 5;

    • Subjects with deficiency of lung and spleen Qi;

    • At least 2 or more allergic symptoms rhinorrhea , sneezing , nasal obstruction and nasal itching for a cumulative period greater than 1 hour per day. These symptoms may be accompanied by itchy and red eyes and tears;

    • Positive srum IgE test;

    • Voluntary written consent.

    Exclusion Criteria:
    • Known chronic disease such as asthma, rhinosinusitis, nasal polyposis;

    • Known severe medical conditions, such as cardiovascular, liver or renal dysfunction, diabetes mellitus, cancers, cerebrovascular diseases, blood system diseases;

    • Concomitant steroid, nonsteroidal anti inflammatory drugs (NSAIDs), anticoagulant, and immunotherapy within past month;

    • Impaired hematological profile and liver / renal function;

    • Known alcohol and / or drug abuse;

    • Known allergic history to any Chinese herbal medicines;

    • Subjects who are pregnant or lactating.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Chinese University of Hong Kong Shatin Hong Kong

    Sponsors and Collaborators

    • Prof. Lin Zhixiu

    Investigators

    • Principal Investigator: Zhixiu Lin, PhD, Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Prof. Lin Zhixiu, Professor, Chinese University of Hong Kong
    ClinicalTrials.gov Identifier:
    NCT04976023
    Other Study ID Numbers:
    • A.Rhinitis study
    First Posted:
    Jul 26, 2021
    Last Update Posted:
    Jun 27, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Prof. Lin Zhixiu, Professor, Chinese University of Hong Kong
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 27, 2022